PD51-04: Medium to Long Term Health-Related Quality of Life and Treatment-Related Side-Effects in Patients treated with a single dose of adjuvant Carboplatin for High-risk Seminoma – results from a pilot study

Walter Cazzaniga*, London, United Kingdom, Adam Pearce, Brisbane, Australia, Chandran Tanabalan, Prabhakar Rajan, Netty Kinsella, Alison Reid, Robert Huddart, David Nicol, London, United Kingdom

Introduction: Medium and long-term side effects of a single dose of adjuvant carboplatin AUC 7 for high-risk stage 1 seminoma are thought to be rare. Persisting symptoms and quality of life impact of treatment for patients have yet to be defined.  Here, we study the medium-long term Health-related quality of life (HRQoL) and treatment-related symptoms of testicular cancer (TC) patients treated with 1xCarboplatin following orchidectomy for high-risk stage 1 seminoma.

Methods: Data obtained from 32 patients divided into 2 treatment groups were analysed (1: Orchidectomy alone – reference group; 2: Orchidectomy + 1xCarboplatin AUC 7). HRQoL was assessed using the validated EQ-5D-5L metric together with a TC specific questionnaire, the EORTC TC26, that has been previously used to study post-treatment side effect severity. To evaluate the medium to long term side effects of treatment all patients included in the study had completed TC treatment 12 to 24 months prior to the administration of the questionnaire

Results: Using the EQ-5D-5L metrics, patients treated with 1xCarboplatin exhibited low and comparable proportions of impairment in the mobility, self-care, and usual activities domains, as compared to the orchidectomy group (0% Vs 0%; 0% Vs 0%; 0% Vs 5.6%; respectively). In contrast, the 1xCarboplatin group, were more prone to report pain or discomfort problems (30.8% Vs 21%).

Patients treated with orchidectomy alone however reported twice the rate of anxiety/depression issues compared to 1xCarboplatin group (58% Vs 30%).With the EORTC TC26 questions, both 1xCarboplatin and orchidectomy alone demonstrated identical medium to long term side effects profiles. Patients who received adjuvant treatment reported almost half the rate of uncertainty concerning their future (39% Vs 69%) and identical self-perceived Health status (81.53% Vs 81.15%), compared to those who had orchiectomy alone

Conclusions: The addition of 1xCarboplatin for high-risk stage1 seminoma does not increase the medium to long term side effects compared to patients with low-risk disease  who underwent orchidectomy alone. Furthermore, adjuvant carboplatin is associated with higher levels of patient perception of care and also reduces anxiety and uncertainty about possible cancer recurrence. Further studies are needed to verify these findings as this information may be a necessary addition to the information provided to patients in contemplating their treatment decision for high-risk stage1 seminoma

Source of Funding: None